HIV-1 resistance and neurocognitive disorders (HAND) currently challenge the success of combination antiretroviral therapy. Moreover, the HIV-1 Protease Inhibitor GRL-142 is a potent agent designed to address these specific hurdles. This state-of-the-art inhibitor demonstrates exceptional potency against wild-type and resistant strains. Additionally, it has the remarkable ability to penetrate the central nervous system (CNS). Consequently, it is now a promising candidate for monotherapy or enhanced therapy regimens.

Molecular Insights into HIV-1 Protease Inhibitor GRL-142 Binding

Recent studies employed all-atom molecular dynamics (MD) simulations to analyze how GRL-142 interacts with the highly resistant p51 variant. Notably, the protein's resistance mechanism involves maintaining structural stability in key active regions. At the same time, it expands its active site cavity. As a result, the inhibitor's canonical backbone binding is disrupted at the P2' functional group moiety. However, GRL-142 exhibits remarkable structural versatility. Specifically, it engages in direct drug-protein interactions that compensate for the loss of crystallographic flap-water. Furthermore, conserved fluorine-mediated interactions help stabilize both the wild-type and p51-G complexes during the binding process.

Energetics and Structural Adaptability

Binding energy calculations using the MMPBSA method revealed that GRL-142 maintains high affinity even against resistant variants. For instance, for the wild-type complex, the calculated energy was -16.1 kcal/mol, which aligns with experimental results. In comparison, the mutant system initially showed slightly less affinity. Nevertheless, the inhibitor underwent a significant binding mode transition. Notably, this novel binding mode achieved an even higher affinity of -18.4 kcal/mol. Therefore, the structural adaptability of GRL-142 is vital for its long-term efficacy against evolving viral strains.

Addressing CNS Complications and HAND

Beyond drug resistance, the CNS-penetrating properties of GRL-142 offer a strategic advantage in treating HAND. Because many current protease inhibitors struggle to cross the blood-brain barrier, the brain often acts as a viral sanctuary. Thus, GRL-142 addresses this gap by maintaining potency in brain tissues. On the other hand, researchers noted that further optimization of the P2' group is necessary. In fact, preserving the backbone binding mechanism against the most resistant strains is critical for future drug design. Similarly, improving the bioactive conformation remains a priority for next-generation antiretrovirals.

Frequently Asked Questions

What makes GRL-142 different from other protease inhibitors?

GRL-142 is a monotherapy-grade inhibitor that combines extreme potency with high CNS penetration and unique structural versatility, allowing it to adapt to resistant variants.

How does the p51 variant resist treatment?

The p51 variant expands its active site cavity and disrupts the hydrogen bond network; however, GRL-142 overcomes this through a binding mode transition and fluorine-mediated stabilization.

Why is CNS penetration important in HIV therapy?

CNS penetration is essential to treat HIV-associated neurocognitive disorders (HAND) and to eliminate viral reservoirs that persist in the brain despite systemic therapy.

Disclaimer: This content is for informational and educational purposes only. It is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Arias A et al. Ligand Versatility and Resistance Mechanism of Monotherapy-Grade HIV-1 Protease Inhibitor GRL-142 Binding the Multidrug Resistant Variant p51: Insights from 1 μs MD Simulations. J Chem Inf Model. 2026 Feb 27. doi: 10.1021/acs.jcim.5c02652. PMID: 41759210.

Aoki M et al. GRL-142 binds to and impairs HIV-1 integrase nuclear localization signal and potently suppresses highly INSTI-resistant HIV-1 variants. Sci Adv. 2023; 9:eadg2955.

Ghosh AK et al. Design and development of highly potent HIV-1 protease inhibitors with a crown-like oxotricyclic core as the P2-ligand to combat multidrug-resistant HIV variants. J Med Chem. 2017; 60:4267-4278.